Building on the announcement made in March of this year, Celator Pharmaceuticals has today (June 4th) presented the Phase III (PIII) findings for its combination therapy VYXEOS (cytarabine and daun
The 2016 American Society of Clinical Oncology (ASCO) annual meeting starts today (3rd June), and it promises to be packed with the latest data and trends from the world of oncology.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.